Efficacy of Recombinant Human Parathyroid Hormone 1-34 and Vitamin K2 Combination Therapy in Postmenopausal Osteoporosis.

Zhang Z, Xia K, Gong W, Mai R, Liu P, Lu Z

Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme28 Aug 2024

PMID39197463DOI10.1055/a-2371-1642PepBankPUB-39197463

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

3 results from studies that gave the peptide. 3 results from people.

01HumanRandomized controlled trialEfficacy outcome
In postmenopausal osteoporosis, adding rhPTH (1-34) to vitamin K2 improved BMD more than vitamin K2 alone.
In plain wordsIn postmenopausal osteoporosis, adding rhPTH (1-34) improved bone density more than vitamin K2 alone.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseBMD versus vitamin K2
Study
n = 77
Comparator
Vitamin K2 alone
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated
Source sentences
Summary
Notably, the combined rhPTH (1-34) and vitamin K2 treatment demonstrated superior efficacy in improving BMD and bone metabolism markers.
3 context sentences(design, population, supporting numbers)
Summary · context
This study aimed to assess the efficacy and safety of a combined recombinant human parathyroid hormone 1-34 [rhPTH (1-34)] and vitamin K2 therapy versus vitamin K2 alone in the treatment of postmenopausal osteoporosis.
Summary · context
A total of 77 postmenopausal osteoporosis patients were randomly divided into two groups.
Summary · context
Patients in one group received vitamin K2 alone, while patients in the other group received a combination of rhPTH (1-34) and vitamin K2.
Report a problemFND-3919746306
02HumanRandomized controlled trialEfficacy outcome
In postmenopausal osteoporosis, adding rhPTH (1-34) improved bone metabolism markers more than vitamin K2 alone.
In plain wordsIn postmenopausal osteoporosis, adding rhPTH (1-34) improved bone metabolism markers more than vitamin K2 alone.
Peptide
Teriparatide (PTH 1-34)
Outcome
Direction not reportedBone metabolism markers versus vitamin K2
Study
n = 77
Comparator
Vitamin K2 alone
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated
Source sentences
Summary
Notably, the combined rhPTH (1-34) and vitamin K2 treatment demonstrated superior efficacy in improving BMD and bone metabolism markers.
3 context sentences(design, population, supporting numbers)
Summary · context
This study aimed to assess the efficacy and safety of a combined recombinant human parathyroid hormone 1-34 [rhPTH (1-34)] and vitamin K2 therapy versus vitamin K2 alone in the treatment of postmenopausal osteoporosis.
Summary · context
A total of 77 postmenopausal osteoporosis patients were randomly divided into two groups.
Summary · context
Patients in one group received vitamin K2 alone, while patients in the other group received a combination of rhPTH (1-34) and vitamin K2.
Report a problemFND-3919746307
03HumanRandomized controlled trialSafety outcome
In postmenopausal osteoporosis, adding rhPTH (1-34) to vitamin K2 did not significantly change adverse reaction incidence versus vitamin K2 alone.
In plain wordsIn postmenopausal osteoporosis, adverse reaction rates did not differ significantly between rhPTH (1-34) plus vitamin K2 and vitamin K2 alone.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeAdverse reactions
Study
n = 77
Comparator
Vitamin K2 alone
Outcome group
Adverse events · Musculoskeletal
Studied dose
Dose not stated
Source sentences
Summary
Furthermore, there was no significant difference in the incidence of adverse reactions between the two groups, indicating the safety of the combined treatment.
3 context sentences(design, population, supporting numbers)
Summary · context
This study aimed to assess the efficacy and safety of a combined recombinant human parathyroid hormone 1-34 [rhPTH (1-34)] and vitamin K2 therapy versus vitamin K2 alone in the treatment of postmenopausal osteoporosis.
Summary · context
A total of 77 postmenopausal osteoporosis patients were randomly divided into two groups.
Summary · context
Patients in one group received vitamin K2 alone, while patients in the other group received a combination of rhPTH (1-34) and vitamin K2.
Report a problemFND-3919746308

Studies that did not test the peptide alone5

In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Teriparatide (PTH 1-34).

04HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome
In postmenopausal osteoporosis, BMD improved with both vitamin K2 alone and rhPTH (1-34) plus vitamin K2.
In plain wordsIn postmenopausal osteoporosis, bone density improved with both vitamin K2 alone and rhPTH (1-34) plus vitamin K2.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseBMD change in both regimens
Study
n = 77
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
Both two treatments improved BMD, blood calcium concentrations, pain scores, and increased osteocalcin and osteoprotegerin levels.
3 context sentences(design, population, supporting numbers)
Summary · context
This study aimed to assess the efficacy and safety of a combined recombinant human parathyroid hormone 1-34 [rhPTH (1-34)] and vitamin K2 therapy versus vitamin K2 alone in the treatment of postmenopausal osteoporosis.
Summary · context
A total of 77 postmenopausal osteoporosis patients were randomly divided into two groups.
Summary · context
Patients in one group received vitamin K2 alone, while patients in the other group received a combination of rhPTH (1-34) and vitamin K2.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-3919746301
05HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome
In postmenopausal osteoporosis, blood calcium concentrations improved with both vitamin K2 alone and rhPTH (1-34) plus vitamin K2.
In plain wordsIn postmenopausal osteoporosis, blood calcium improved with both vitamin K2 alone and rhPTH (1-34) plus vitamin K2.
Peptide
Teriparatide (PTH 1-34)
Outcome
Direction not reportedBlood calcium change in both regimens
Study
n = 77
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
Both two treatments improved BMD, blood calcium concentrations, pain scores, and increased osteocalcin and osteoprotegerin levels.
3 context sentences(design, population, supporting numbers)
Summary · context
This study aimed to assess the efficacy and safety of a combined recombinant human parathyroid hormone 1-34 [rhPTH (1-34)] and vitamin K2 therapy versus vitamin K2 alone in the treatment of postmenopausal osteoporosis.
Summary · context
A total of 77 postmenopausal osteoporosis patients were randomly divided into two groups.
Summary · context
Patients in one group received vitamin K2 alone, while patients in the other group received a combination of rhPTH (1-34) and vitamin K2.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-3919746302
06HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome
In postmenopausal osteoporosis, pain scores improved with both vitamin K2 alone and rhPTH (1-34) plus vitamin K2.
In plain wordsIn postmenopausal osteoporosis, pain scores improved with both vitamin K2 alone and rhPTH (1-34) plus vitamin K2.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreasePain score change in both regimens
Study
n = 77
Outcome group
Pain · Musculoskeletal
Source sentences
Summary
Both two treatments improved BMD, blood calcium concentrations, pain scores, and increased osteocalcin and osteoprotegerin levels.
3 context sentences(design, population, supporting numbers)
Summary · context
This study aimed to assess the efficacy and safety of a combined recombinant human parathyroid hormone 1-34 [rhPTH (1-34)] and vitamin K2 therapy versus vitamin K2 alone in the treatment of postmenopausal osteoporosis.
Summary · context
A total of 77 postmenopausal osteoporosis patients were randomly divided into two groups.
Summary · context
Patients in one group received vitamin K2 alone, while patients in the other group received a combination of rhPTH (1-34) and vitamin K2.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-3919746303
07HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome
In postmenopausal osteoporosis, osteocalcin increased with both vitamin K2 alone and rhPTH (1-34) plus vitamin K2.
In plain wordsIn postmenopausal osteoporosis, osteocalcin increased with both vitamin K2 alone and rhPTH (1-34) plus vitamin K2.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseOsteocalcin change in both regimens
Study
n = 77
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
Both two treatments improved BMD, blood calcium concentrations, pain scores, and increased osteocalcin and osteoprotegerin levels.
3 context sentences(design, population, supporting numbers)
Summary · context
This study aimed to assess the efficacy and safety of a combined recombinant human parathyroid hormone 1-34 [rhPTH (1-34)] and vitamin K2 therapy versus vitamin K2 alone in the treatment of postmenopausal osteoporosis.
Summary · context
A total of 77 postmenopausal osteoporosis patients were randomly divided into two groups.
Summary · context
Patients in one group received vitamin K2 alone, while patients in the other group received a combination of rhPTH (1-34) and vitamin K2.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-3919746304
08HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome
In postmenopausal osteoporosis, osteoprotegerin increased with both vitamin K2 alone and rhPTH (1-34) plus vitamin K2.
In plain wordsIn postmenopausal osteoporosis, osteoprotegerin increased with both vitamin K2 alone and rhPTH (1-34) plus vitamin K2.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseOsteoprotegerin change in both regimens
Study
n = 77
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
Both two treatments improved BMD, blood calcium concentrations, pain scores, and increased osteocalcin and osteoprotegerin levels.
3 context sentences(design, population, supporting numbers)
Summary · context
This study aimed to assess the efficacy and safety of a combined recombinant human parathyroid hormone 1-34 [rhPTH (1-34)] and vitamin K2 therapy versus vitamin K2 alone in the treatment of postmenopausal osteoporosis.
Summary · context
A total of 77 postmenopausal osteoporosis patients were randomly divided into two groups.
Summary · context
Patients in one group received vitamin K2 alone, while patients in the other group received a combination of rhPTH (1-34) and vitamin K2.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-3919746305

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.